



JAMMU AND KASHMIR MEDICAL SUPPLIES CORPORATION LTD.

(Public Sector Undertaking of Govt of Jammu & Kashmir)

Corporate Head Office: Plot No. 56, Friends Colony Satyam Road, Telukta Nagar, Jammu

Corporate Office Kashmir: at Baramulla Bypass (Near Hajj House) Srinagar

Telephone: 0191 2580842, Fax: 0191 2581845 (Jammu), Teletax: 0194 2492062 (Srinagar)

Notification:

E bid for the finalization of Rate Contract under e-NIT reference No. JKMSCL/Allopathic Medicines /2022/541 dated 20.08.2022 wherein following have been projected as proprietary / Patient Products

S No.	Name of Item	Item code	Name of Bidder/ Importer	Name of Manufacturer
1.	Inj. Omalizumab 150mg (Sterile Power), Per Pack Containing 150 mg vial and solvent of 2ml ampoule	item code 1674	M/S Reliance Life Sciences Pvt. Ltd.	M/S Reliance Life Sciences Pvt. Ltd. Dhurbhai Ambani Life Sciences Centre, R 282, TTC Area of MIDC, Thane - Belapur Road, Rabale, Navi Mumbai - 400701
2.	Heparin Topical solution 1000IU/ml, 5ml bottle	item code 1675	M/S Troika Pharmaceuticals Limited, Commerce House 1, Opp. Rajvansh Apartment, Satya Marg, Bodakdev, Ahmedabad 380054	M/S Troika Pharmaceuticals Limited, Commerce House 1, Opp. Rajvansh Apartment, Satya Marg, Bodakdev, Ahmedabad 380054
	Nasal Spray Methyl Cobalamine, 250mcg/spray, 2.3ml bottle (46 sprays)	item code 1677		
	Spray Diclofenac Diethylamide 4.64% w/v (with QPS Technology) 30 ml bottle	item code 1676		
3.	Inj. Somatropin Biosynthetic-r-DNA origin (HGH), PFS, 15mg/1.5ml.	item code 1659	M/S Novo Nordisk India Private Limited, Plot no 32 EPIP AREA WHITEFIELD	Novo Nordisk-Denmark
	Inj. Somatropin Biosynthetic-r-DNA origin (HGH), PFS, 10mg/1.5ml	item code 1659		
	Biphasic Insulin Aspart 100U/ml (Mixture of Insulin Aspart (30%) + Insulin Aspart Protamine (70%)), 3ml penfill	item code 1660		
	Insulin Aspart 100U/ml, 3ml penfill	item code 1661		
	Insulin Degludec 100U/ml, 3ml penfill.	item code 1662		
	Insulin Degludec Aspart (70% Degludec and 30% Aspart) 100U/ml, 3ml penfill.	item code 1663		
	Tab. Semaglutide 3mg	item code 1664		
	Tab. Semaglutide 7mg	item code 1665		
Tab. Semaglutide 14mg	item code 1666			
4.	Inj. Pneumococcalm	item code	M/S MSD PHARMACEUTICALS	M/S Merck Sharp &

	Polysaccharide Vaccine 23(PPSV 23), 0.5ml PFS	1673	PVT LTD, Wework Enam Sambhav Plot C 20 G Block Bandra Kurla Complex Mumbai 400051	Dohma B.V-Netherland
5.	Cream Framycetin 1% w/v . 100gram tube	Item code 1686	M/S ENCUBE ETHICALS PRIVATE LIMITED, 803 B WING HDIL KALEDONIA SAHAR ROAD ANDHERI EAST MUMBAI	M/S ENCUBE ETHICALS PRIVATE LIMITED, Plot No C-1, Madkaim Industrial Estate Madkaim ,Ponda Goa.
6.	Inj. Goserelin Acetate 3.6mg PFS	Item code 1678	M/S AstraZeneca Pharma India Limited, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore	AstraZeneca UK Limited 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA-UK
	Inj. Goserelin Acetate 10.8mg PFS	Item code 1679		
	Tab. Olaparib 150mg film coated	Item code 1680		
	Tab. Olaparib 100mg film coated	Item code 1681		
	Tab. Osimertinib 80mg	Item code 1682		
	Inj. Durvalumab 120mg/2.4ml	Item code 1683		
	Inj. Durvalumab 500mg/10ml	Item code 1684		
7.	Inj. Pneumococcal Polysaccharide Conjugate Vaccine 13-valent, 0.5ml PFS	Item code 1687	M/S Pfizer Limited, The Capital 1802 1901 G Block Bandra Kurla Complex Bandra East Mumbai	M/S Pfizer Limited, USA

It is notified that in case any bidder / manufacturer / importer have objection / comments related to above mention medicines in terms of Proprietary / patent of the item mentioned above tender under reference No: JKMSCL/Allopathic Medicines /2022/541 dated 20.08.2022, as claimed by the bidder. The reply of the same with proper justification /documents through e-mail on mdjkmscl2@gmail.com / gmjkmscl1@gmail.com within 5 days from the date of issuance of this notification. Thereafter no objection shall be entertained. The details of Proprietary /Patent Certificates and tendered specification are available on website of JKMSCL i.e www.jkmsclbusiness.com



 General Manager (P&S/Drugs)

 JKMSCL

No. JKMSCL\GM\Drugs\2023\11763-67

Dated: 13.02.2023

Copy for information to the:

1. Managing Director -JKMSCL
2. Joint Director, information Department Jammu/Srinagar with the request to kindly publish the notification in the leading local newspapers in order to give the notification wider publicity.
3. Financial Advisor -JKMSCL
4. General Manager (Administration) -JKMSCL
5. Assistant Programmer -JKMSCL to upload the notification on the official website of JKMSCL
6. Office file



Pfizer Limited

The Capital, 1802/1901,
Plot No C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051
Tel +91 22 6693 2000 Fax +91 22 2654 0274

09th February 2023

To,
The Managing Director,
Jammu and Kashmir Medical Supplies Corporation Limited
Jammu & Kashmir,
Jammu

Dear Sir/Madam,

Subject: PAC Items in Tender NIT-541

Reference Tender no. JKMSCL/Allopathic Drugs 2022/541 DATED: 20-08-2022

With reference to the above-mentioned tender number, We M/s. Pfizer Limited do hereby highlight that the product quoted in the Tender is an imported, patented and proprietary product.

Enclosed Patent and Proprietary Article Certificate for your reference, we have already enclosed patent and PAC in the Technical Bid. **(Pls. Refer Page No. 53-A and 53-B)**

The quoted product would fall under single bid category, considering it as a patented product.

Tender S. No.	Item Code	Product Description	Page No In Technical Bid
22	1687	Inj. Pneumococcal Polysaccharide Conjugate Vaccine 13 Valent, 0.5ml PFS Brand Name: PREVENAR 13 PFS	53-A & 53-B

In order to save valuable time of your esteemed organization and to timely provide quality lifesaving drugs to patient, we request you to consider our bid.

For M/s. Pfizer Limited

Vijay Pangle
Manager-Tender and Contracting



CIN: L24231MH1950PLC008311
Email ID: contactus.india@pfizer.com
Website: www.pfizerltd.co.in



Proprietary Article Certificate

It is certified that "Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., 13- valent", sold under the trade name Prevenar 13[®] is a proprietary product of Wyeth LLC, an affiliate company of Pfizer Inc., USA.

The above product is solely Imported and Marketed in India by Pfizer Limited, located at The Capital-A wing, 1802, 18th Floor, Plot No. C-70, "G" Block, Bandra Kurla Complex, Bandra (E), Mumbai 400051, an indirect wholly-owned subsidiary of Pfizer Inc, USA.

It is confirmed that no other company is authorized to manufacture / import, "Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., 13-Valent" (Prevenar 13[®]) for further sales in India.

Pfizer Inc.

DocuSigned by:

Bryan Zielinski

AB405639E1E349L

Bryan C. Zielinski

Vice President and Chief Patent Counsel

Date: November 23, 2022



**INTELLECTUAL
PROPERTY INDIA**

PATENTS | DESIGNS | TRADE MARKS
GEOGRAPHICAL INDICATIONS



सत्यमेव जयते

भारत सरकार
GOVERNMENT OF INDIA

पेटेंट कार्यालय
THE PATENT OFFICE

पेटेंट प्रमाणपत्र
PATENT CERTIFICATE
(Rule 74 Of The Patents Rules)

क्रमांक : 011103526
SL No :



पेटेंट सं. / Patent No. : 288364
आवेदन सं. / Application No. : 9394/DELNP/2008
फाइल करने की तारीख / Date of Filing : 19/04/2007
पेटेंटी / Patentee : WYETH LLC

प्रमाणित किया जाता है कि पेटेंटी को उपरोक्त आवेदन में यथाप्रकटित "A FORMULATION WHICH STABILIZES A POLYSACCHARIDE-PROTEIN CONJUGATE" नामक आविष्कार के लिए, पेटेंट अधिनियम, १९७० के उपबंधों के अनुसार आज तारीख 19th day of April 2007 से बीस वर्ष की अवधि के लिए पेटेंट अनुदान किया गया है।

It is hereby certified that a patent has been granted to the patentee for an invention entitled "A FORMULATION WHICH STABILIZES A POLYSACCHARIDE-PROTEIN CONJUGATE" as disclosed in the above mentioned application for the term of 20 years from the 19th day of April 2007 in accordance with the provisions of the Patents Act, 1970.



Date of Grant: 13/10/2017

OK Gupta

Controller of Patent

टिप्पणी - इस पेटेंट के नवीकरण के लिए फीस, यदि इसे बनाए रखा जाना है, 19th day of April 2009 को और उसके पश्चात प्रत्येक वर्ष में उसी दिन देना होगा।

Note. - The fees for renewal of this patent, if it is to be maintained will fall / has fallen due on 19th day of April 2009 and on the same day in every year thereafter.

Date: 07.02.2023

Proprietary Article Certificate

To whomsoever it may concern

We hereby declare that M/s. Troikaa Pharmaceuticals Limited is the applicant for Patent Indian application covering the Product Phlebotroy QPS 5ml, contains Heparin Sodium 1000IU/ml Topical Solution.

The said product is approved by DCGI for Topical route of administration.

We also certify that above said product is our proprietary product and we are the only manufacturer of said product by QPS Technology.

Thanking you,

For Troikaa Pharmaceuticals Limited



Rajesh Dutta Gupta
GM- Institution Business



Troikaa Pharmaceuticals Limited





Date: 07.02.2023

Proprietary Article Certificate

To whomsoever it may concern

We hereby declare that M/s. Troikaa Pharmaceuticals Limited is the Patent Holder of Novel Composition of Non-Aqueous Topical Solution sold under the brand name: Dynapar QPS 30ml (DICLOFENAC DIETHYLAMINE 4.64% W/V ONLY TOPICAL SOLUTION 30 ML BOTTLE).

The said formulation is approved by DCGI for Topical route of administration.

We also certify that said product is our proprietary product.

Thanking you,

For Troikaa Pharmaceuticals Limited

Rajesh Dutta Gupta
GM- Institution Business



Troikaa Pharmaceuticals Limited

Regd. Office : 'Commerce House - 1', Satya Marg, Bodakdev, Ahmedabad-380 054. Ph.: (079) 26856242/43/44/45, Fax: 26856246



Scanned with OKEN Scanner



Imagine. Innovate

Date: 07.02.2023

Proprietary Article Certificate

To whomsoever it may concern

We hereby declare that M/s. Troikaa Pharmaceuticals Limited is having product NASO B12 spray, contains Methylcobalamin Nasal Spray 250mcg/spray.

The said product is approved by DCGI for Treatment of vitamins B12 deficiency in patients without having neurological involvement.

We also certify that above said product is our proprietary product and we are the only manufacturer of the said product NASO B12 spray.

Thanking you,

For Troikaa Pharmaceuticals Limited

Rajesh Dutta Gupta
GM- Institution Business



Troikaa Pharmaceuticals Limited

Regd. Office : 'Commerce House - 1', Satya Marg, Bodakdev, Ahmedabad-380 054, Ph.: (079) 26856242/43/44/45, Fax: 26856246
Corporate Identity Number: U24100GJ1994PLC022162. Email: troikaa@troikaapharma.com. Website: www.troikaa.com



Scanned with OKEN Scanner


Reliance Life Sciences Pvt Ltd.
R-282, TTC Area of MIDC Thane - Belapur Road,
Rabale, Navi Mumbai - 400701, Maharashtra, INDIA.
Phone: +91-22-4067 8000 • Fax: +91-22-4067 8099



TO WHOM SO EVER IT MAY CONCERN

We do hereby state that M/s. Reliance Life Sciences Pvt. Ltd. is the indigenous manufacturer of Inj. Omalizumab 150 mg vial in India. No company other than Reliance Life Sciences is manufacturing the above-said drug in India.

Reliance Life Sciences Pvt. Ltd


Authorized Signatory

Vimal Kant Singh
Regional Head – Institution
Reliance Life Sciences Pvt. Ltd.

Gm (Res)


10/02/23

Mo (Res)


11/2/2023



556
Gm - 16/mssc/23
11/02/2023

AstraZeneca 

AstraZeneca UK Limited
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge, CB2 0AA
United Kingdom
T. +44 (0) 20 3749 5000

astrazeneca.com

To Whomsoever it may concern

Proprietary Certificate

This is to certify and confirm that M/s. AstraZeneca UK Limited, Silk Road Business Park, SK 10 2NA Macclesfield, Cheshire, United Kingdom is manufacturer of Olaparib (Lynparza 100mg and 150mg) film coated tablets and it is a proprietary product of AstraZeneca UK Limited.

AstraZeneca Pharma India Limited, Bangalore, India is the sole importer and marketer of the Drug in India.

AstraZeneca Pharma India Limited and AstraZeneca UK are part of the AstraZeneca group of companies.

This certificate is valid for a period of One Year from the date of issue.

Signed for and on behalf of
AstraZeneca UK Limited



Victoria Roden
Senior Regulatory Affairs Group Director
Oncology Regulatory Science, Strategy and Excellence

Date: 27th April 2022

AstraZeneca UK Limited
Registered Office
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA

AstraZeneca UK Limited is a subsidiary of AstraZeneca PLC
Registered in England No. 3574842
Registered office: 1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom

AstraZeneca AB
SE-151 85 Södertälje, Sweden
T: +46 8 553 260 00
F: +46 8 553 200 00
astrazeneca.com

To Whomsoever it may concern

Proprietary Certificate

This is to certify and confirm that M/s. AstraZeneca AB, Sweden, S-151 85, Södertälje, Sweden (Secondary packaging and distribution) is manufacturer of Durvalumab Intravenous Infusion 120mg (120mg/2.4mL) & 500 mg (500mg/10mL) in 10 ml. Brand Name: Imfinzi® (hereinafter referred as "Drug") and it is a proprietary product of AstraZeneca AB, Sweden.

AstraZeneca Pharma India Limited, Bangalore, India is the sole importer and marketer of the Drug in India.

AstraZeneca Pharma India Limited and AstraZeneca AB, Sweden are part of the AstraZeneca group of companies.

This certificate is valid for a period of One Year from the date of issue.

For and on behalf of
AstraZeneca AB (publ)


Helene Thelin
Senior Regulatory Affairs Group Director

Date: May 25, 2022



Reg Office AstraZeneca AB (publ)
SE-151 85 Södertälje, Sweden
Reg No 556011-7482

AstraZeneca AB
SE-151 85 Södertälje, Sweden
T: +46 8 553 260 00
F: +46 8 553 290 00
astrazeneca.com

To Whomsoever it may concern

Proprietary Certificate


This is to certify and confirm that M/s. AstraZeneca AB, Sweden, S-151 85, Södertälje, Sweden is manufacturer of Osimertinib 40mg and 80mg - Brand Name: Tagrisso (hereinafter referred as "Drug") and it is a proprietary product of AstraZeneca AB, Sweden.

AstraZeneca Pharma India Limited, Bangalore, India is the sole importer and marketer of the Drug in India.

AstraZeneca Pharma India Limited and AstraZeneca AB, Sweden are part of the AstraZeneca group of companies.

This certificate is valid for a period of one year from the date of issue.

For and on behalf of
AstraZeneca AB (publ)



.....
Karin Dotevall
Regulatory Affairs Group Director

Date: April 20, 2022



Reg Office AstraZeneca AB (publ)
SE-151 85 Södertälje, Sweden
Reg No 556011-7482



AstraZeneca UK Limited
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
T: +44 (0) 20 3745 9770

astrazeneca.com

To Whomsoever It May Concern

Proprietary Certificate


This is to certify and confirm that M/s. AstraZeneca UK Limited, Silk Road Business Park, SK10 2NA Macclesfield, Cheshire, United Kingdom is manufacturer of Goserelin Acetate Injection 3.6mg, Goserelin Acetate Injection 10.8 mg Brand Name: Zoladex 3.6mg and Zoladex 10.8mg (hereinafter referred as "Drug") and it is a proprietary product of AstraZeneca UK Limited.

AstraZeneca Pharma India Limited, Bangalore, India is the sole importer and marketer of the Drug in India.

AstraZeneca Pharma India Limited and AstraZeneca UK are part of the AstraZeneca group of companies.

This certificate is valid for a period of One Year from the date of issue.

Signed for and on behalf of
AstraZeneca UK Limited



Victoria Roden
Senior Regulatory Affairs Group Director
AstraZeneca UK Limited

Date: 5th June 2022

AstraZeneca UK Limited
Registered Office
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA

AstraZeneca UK Limited is a subsidiary of AstraZeneca PLC
Registered in England No: 3674842
Registered office: 1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge, CB2 0AA,
United Kingdom.



changing
diabetes
Bangalore
09 February 2023

To
The Managing Director,
Jammu and Kashmir Medical Supplies Corporation Limited
Jammu & Kashmir, Jammu

Subject : Proprietary Items in tender NIT-541

Dear Sir,

Please refer to your tender no. JKMSCL/Allopathic Drugs 2022 / 541 DATED: 20-08-2022, in reference to the same we would like submit as under,

That we have quoted the following items in this tender, these are proprietary Items and are essentially required by the hospitals,

We had already submitted the PAC certificate for these items in the technical bid of this tender vide the page nos (130-F To 130-H)(357-A to 357-F) detailed below,

Tender S.No	Item Code	Product Description	Category
127	1659	Inj. Somatropin Biosynthetic-r-DNA origin(HGH), PFS, 15mg/ 1.5ml.	Proprietary
128	1659	Inj. Somatropin Biosynthetic-r-DNA origin(HGH), PFS,10mg/ 1.5ml	Proprietary
129	1660	Biphasic Insulin Aspart 100U/ml (Mixture of Insulin Aspart (30%) + Insulin Aspart Protamine (70%), 3ml penfill	Proprietary
130	1661	Insulin Aspart 100U/ml,3ml penfill	Proprietary
131	1662	Insulin Degludec 100U/ml, 3ml penfill	Proprietary
132	1663	Insulin Degludec Aspart (70%Degludec and 30% Aspart) 100U/ml, 3ml penfill	Proprietary
133	1664	Tab. Semaglutide 3mg	Proprietary
134	1665	Tab. Semaglutide 7mg	Proprietary
134	1666	Tab. Semaglutide 14mg	Proprietary

Since this item is Proprietary/Patented product, and may have been remained single quoted in this tender , you are kindly requested to consider this item as Proprietary item rather than single quoted.

Thanking you and always assuring you always our best services.

Yours truly,
For Novo Nordisk India Private Limited

Suryamani Jena
Suryamani Jena
National Account Manager
institutionsales@novonordisk.com
surj@novonordisk.com



DGM (P&S)
[Signature]
10/2/23

MO (P&S)

[Signature]
11/2/2023

Regd. Office
Novo Nordisk India Private Limited
CIN: U28111KA1994PTC015194
Plot No.32, 47-50,
EPIP Area, Whitefield
Bangalore-560 066,
India

Telephone:
+91 80 40303200
Fax:
+91 8041123518

Postal Address:
P.O. Box No. 5225, GPO
Bangalore - 560 001, India
P.O. Box No. 66 81, Whitefield
Bangalore - 560 066, India

Internet:
www.novonordisk.com

SSO for-4/mse/fb3
10/2/23



PH: 0832-2459230 /2459226
Fax: 0832-2459223
website: www.dfda.goa.gov.in

No. 502/MFG/CERT/DFDA/2022/ 6954
Government of Goa
Dte. of Food & Drugs Admn.,
"Dhanwantari"
Opp. Shrine of the Holy Cross
Bambolim, Goa - 403 202
Dated: 21/3 /2022

CERTIFICATE

This is to certify that M/s. Encube Ethicals Pvt. Ltd, situated at Plot No. C-1, Madkaim Industrial Estate, Madkaim, Ponda Goa is holding valid Drugs Manufacturing Licenses bearing Nos. 361 and 362, dated 03.03.1998 and renewed up to 31.12.2026, issued by this Directorate in Form 25 and Form 28 respectively under the provisions of Drugs and Cosmetics Act 1940 and Rules made there under, to manufacture Drugs/Drug formulations at the above address.

Under the aforesaid license No. 362, the firm is permitted to manufacture Framycetin Skin Cream granted vide permission no. 502(149)/MFG/DFDA/2020/2067, dated 26.10.2020 and the said product is a Patent or Proprietary Product as per section 3 (h) (ii) of the Drugs & Cosmetics Act and Marketed under the brand name **Soframycin Skin Cream.**

This certificate is issued at the request of M/s. Encube Ethicals Pvt. Ltd, situated at Plot No C-1, Madkaim Industrial Estate, Madkaim, Ponda Goa for the purpose of Government tender / registration.



Jyoti J. Sardesai
Jyoti J. Sardesai
Director
Food & Drugs Admn., Bambolim Goa

"Wear Mask,

Maintain Hand Hygiene,

Follow Social Distancing"



Merck Sharp & Dohme BV
Waarderweg 39
2031 BN Haarlem
The Netherlands
T: +31 (0)20 4616000
F: +31 (0)20 4616001
www.msd.com



To Whom It May Concern:


Subject: Proprietary Article Certificate of Pneumovax 23 (Pneumococcal Polysaccharide Vaccine)

This is to certify that Merck Sharp & Dohme BV, Waarderweg 39, 2031 BN Haarlem, The Netherlands, is the registered site for **Pneumovax 23** (Pneumococcal Polysaccharide Vaccine) supply to India.

We further certify that **Pneumovax 23** is our proprietary product.

This product is presently being imported and marketed in India by our affiliate MSD Pharmaceuticals Pvt.Ltd.

Haarlem, 24 February 2022


Kathrin Abelen
Executive Director Quality Operations
Qualified Person
MMD Haarlem, The Netherlands

*For India the registered manufacturer is the responsible site for final release

